Latin America's challenge to create access to innovative therapies

31 March 2023
latin_america_shutterstock_large

Improving the availability of innovative medicines in Latin America is a key priority for the pharmaceutical industry, policymakers, and patients.

That was the conclusion of the first study on access to innovative therapies, which was launched by Fifarma, the trade group for Latin America's pharmaceutical industry.

The study analyzed the availability and time taken to access innovative medicines for orphan diseases and oncologic illness in eight Latin American countries including Brazil, Chile, Mexico, Peru, Argentina and Costa Rica.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical